Article
Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.
PloS one - 1 Jan 2016
Kiessling Michael K, Curioni-Fontecedro Alessandra, Samaras Panagiotis, Lang Silvia, Scharl Michael, Aguzzi Adriano, Oldrige Derek A, Maris John M, Rogler Gerhard
Abstract excerpt
High-risk neuroblastoma remains lethal in about 50% of patients despite multimodal treatment. Recent attempts to identify molecular targets for specific therapies have shown that Neuroblastoma RAS (NRAS) is significantly mutated in a small number of patients. However, few inhibitors for the potential treatment for NRAS mutant neuroblastoma have been investigated so far. In this in-vitro study, we show that MEK...
Topics
- Antineoplastic Agents
- Cell Line, Tumor
- Drug Delivery Systems
- Everolimus
- Female
- GTP Phosphohydrolases
- Humans
- Membrane Proteins
- Mitogen-Activated Protein Kinase Kinases
- Morpholines
- Mutation
- Neuroblastoma
- Phosphatidylinositol 3-Kinases